In the last trading session, 2.32 million shares of the Heron Therapeutics Inc (NASDAQ:HRTX) were traded, and its beta was 1.80. Most recently the company’s share price was $1.77, and it changed around -$0.14 or -7.33% from the last close, which brings the market valuation of the company to $268.46M. HRTX currently trades at a discount to its 52-week high of $3.93, offering almost -122.03% off that amount. The share price’s 52-week low was $0.50, which indicates that the current value has risen by an impressive 71.75% since then. We note from Heron Therapeutics Inc’s average daily trading volume that its 10-day average is 1.48 million shares, with the 3-month average coming to 2.05 million.
Heron Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.20. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended HRTX as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Heron Therapeutics Inc is expected to report earnings per share of -0.03 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Instantly HRTX has showed a red trend with a performance of -7.33% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.9950 on recent trading dayincreased the stock’s daily price by 11.28%. The company’s shares are currently up 4.12% year-to-date, but still down -0.56% over the last five days. On the other hand, Heron Therapeutics Inc (NASDAQ:HRTX) is -11.06% down in the 30-day period. We can see from the shorts that 30.64 million shares have been sold at a short interest cover period of 15.54 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 74.71% from its current value. Analyst projections state that HRTX is forecast to be at a low of $5 and a high of $9.
Heron Therapeutics Inc (HRTX) estimates and forecasts
Heron Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -23.71 percent over the past six months and at a 86.25% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 82.40% in revenue this quarter, and will report an increase of 57.10% in the next quarter. The year-over-year growth rate is expected to be 16.10%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 36.62M in revenue for the current quarter. 4 analysts expect Heron Therapeutics Inc to make 40.2M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 31.43M and 34.23M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 16.50%. Forecasts for the next quarter put sales growth at 17.40%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20.01%. Heron Therapeutics Inc earnings are expected to increase by 84.19% in 2024, but the outlook is positive 47.50% per year for the next five years.
HRTX Dividends
Heron Therapeutics Inc’s next quarterly earnings report is expected to be released in November.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.69% of Heron Therapeutics Inc shares, and 86.73% of them are in the hands of institutional investors. The stock currently has a share float of 87.33%. Heron Therapeutics Inc stock is held by 227.0 institutions, with RUBRIC CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 17.6678% of the shares, which is about 26.71 million shares worth $93.5 million.
VANGUARD GROUP INC, with 5.6984% or 8.62 million shares worth $30.16 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
